What We're Reading: Page 22
Industry reads hand-picked by our editors
Mar 27, 2025
-
The New York Times
Remedy Supported by Kennedy Leaves Some Measles Patients More Ill
-
The Wall Street Journal
U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine
-
The Financial Times
Elliott held talks with private equity as it considered new Bayer campaign
-
ApexOnco
AACR 2025 preview – distressed biotechs seek redemption
Mar 26, 2025
-
Reuters
Trump turbulence stalls large pharma and biotech deals, bankers say
-
Boston Business Journal
Lyndra Therapeutics winds down operations
-
The Washington Post
Vaccine skeptic hired to head federal study of immunizations and autism
Mar 25, 2025
-
The Wall Street Journal
The Longevity Business Is Booming—and Its Scientists Are Clashing
-
The Atlantic
An ‘Impossible’ Disease Outbreak in the Alps
-
Associated Press
Trump will nominate acting CDC director Susan Monarez for the position, White House official says
Mar 24, 2025
Mar 21, 2025
-
Regulatory Focus
Some FDA staff considering quitting due to Trump’s RTO policy
-
Reuters
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
-
The New York Times
A.I. Saved His Life by Discovering New Uses for Old Drugs
-
Fierce Biotech
‘Not a cost-cutting exercise’: Novo Nordisk reshapes R&D setup
Mar 20, 2025
Mar 19, 2025
-
The Wall Street Journal
Trump Administration Weighing Major Cuts to Funding for Domestic HIV Prevention
-
Bloomberg
Pfizer Looks to Exit Haleon With Final Stake Sale
-
Fierce Pharma
Novartis to lay off 427 staffers amid marketing model rework
Previous
